CL2023000884A1 - Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna. - Google Patents

Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna.

Info

Publication number
CL2023000884A1
CL2023000884A1 CL2023000884A CL2023000884A CL2023000884A1 CL 2023000884 A1 CL2023000884 A1 CL 2023000884A1 CL 2023000884 A CL2023000884 A CL 2023000884A CL 2023000884 A CL2023000884 A CL 2023000884A CL 2023000884 A1 CL2023000884 A1 CL 2023000884A1
Authority
CL
Chile
Prior art keywords
lukb
staphylococcus aureus
variant polypeptides
luka
vaccine compositions
Prior art date
Application number
CL2023000884A
Other languages
English (en)
Spanish (es)
Inventor
Jinquan Luo
Jeroen Geurtsen
Sandeep Somani
Brian Morrow
Sergey Konstantinov
Peter T Buckley
Victor J Torres
Original Assignee
Janssen Pharmaceuticals Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ New York filed Critical Janssen Pharmaceuticals Inc
Publication of CL2023000884A1 publication Critical patent/CL2023000884A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2023000884A 2020-09-28 2023-03-27 Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna. CL2023000884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063084273P 2020-09-28 2020-09-28

Publications (1)

Publication Number Publication Date
CL2023000884A1 true CL2023000884A1 (es) 2023-09-29

Family

ID=80846955

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000884A CL2023000884A1 (es) 2020-09-28 2023-03-27 Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna.

Country Status (15)

Country Link
US (1) US20240050546A1 (https=)
EP (1) EP4216982A4 (https=)
JP (1) JP2023544300A (https=)
KR (1) KR20230091911A (https=)
CN (1) CN116670158A (https=)
AR (1) AR123635A1 (https=)
AU (1) AU2021350860A1 (https=)
CA (1) CA3195895A1 (https=)
CL (1) CL2023000884A1 (https=)
CO (1) CO2023004198A2 (https=)
IL (1) IL301406A (https=)
JO (1) JOP20230065A1 (https=)
MX (1) MX2023003581A (https=)
NZ (1) NZ798451A (https=)
WO (1) WO2022067255A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
EP4015523A1 (en) * 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
EP3638286A4 (en) * 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Also Published As

Publication number Publication date
US20240050546A1 (en) 2024-02-15
IL301406A (en) 2023-05-01
JP2023544300A (ja) 2023-10-23
AR123635A1 (es) 2022-12-28
EP4216982A4 (en) 2025-03-19
WO2022067255A2 (en) 2022-03-31
CN116670158A (zh) 2023-08-29
JOP20230065A1 (ar) 2023-03-28
CA3195895A1 (en) 2022-03-31
AU2021350860A1 (en) 2023-05-04
EP4216982A2 (en) 2023-08-02
KR20230091911A (ko) 2023-06-23
CO2023004198A2 (es) 2023-07-31
MX2023003581A (es) 2023-06-21
WO2022067255A3 (en) 2022-04-28
NZ798451A (en) 2024-11-29

Similar Documents

Publication Publication Date Title
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
PY1548374A (es) Vacunas de FMDV recombinante y usos de las mismas
AR115101A1 (es) Composiciones para el control de patógenos y usos de las mismas
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
MX2017012207A (es) Derivados de aceite natural maleatado a manera de ingredientes agroquimicos inertes.
CL2017002694A1 (es) Métodos para mejora hidráulica de cultivos
AR115069A1 (es) Virus vacuna quimérico sintético
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
MX2019009606A (es) Bis-compuestos para dispositivos opticamente activos.
MX2023012390A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
MX360084B (es) Composicion de champu que comprende matriz de gel e histidina.
CO2021017697A2 (es) Mejoramientos en o relacionados con compuestos orgánicos
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
CO2019003424A2 (es) Extracto de planta impregnado de alulosa y método de preparación para el mismo
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
CL2023000884A1 (es) Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna.
CL2019002516A1 (es) Composiciones cosméticas para el cuidado de la piel.
MX383442B (es) Composiciones para el cuidado bucal y métodos para blanquear los dientes.
MX2017004535A (es) Mejoramientos en o con relacion a compuestos organicos.
MX2019005495A (es) Composicion para el cuidado bucal.
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
MX2018006414A (es) Cabezal dispensador para un dispositivo dispensador de gatillo con un muelle de retorno.
CL2025000955A1 (es) Construcción de vacuna y sus usos